Quick Answer
Curanex Pharmaceuticals Inc reported Net Income of -$4.23 million for fiscal year 2025.
Curanex Pharmaceuticals Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$4.23M -1068.8% |
-$361.5K | — |
| Diluted EPS | -$0.17 -466.7% |
-$0.03 | — |
| Total Assets | $11.58M +2135.8% |
$517.9K | — |
| Stockholders Equity | $11.22M +2128.8% |
$503.4K +737.7% |
$60.1K |
| R&D Expense | $2.99M | — | — |
| Operating Income | -$4.24M -1061.2% |
-$365.1K | — |
| Shares Outstanding | 28.34M +18.1% |
24.00M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$954.1K | -946.5% | -1481.0% |
| Diluted EPS | September 30, 2025 | -$0.04 | +0.0% | — |
| Total Assets | September 30, 2025 | $14.48M | — | +1739.3% |
| Stockholders Equity | September 30, 2025 | $14.29M | +2189.8% | +4579.4% |
| R&D Expense | September 30, 2025 | $677.5K | — | — |
| Operating Income | September 30, 2025 | -$951.3K | -919.7% | -1549.9% |
| Shares Outstanding | September 30, 2025 | 28.34M | — | +18.1% |
- Curanex Pharmaceuticals Inc reported Net Income of -$4.23 million for fiscal year 2025.
- Curanex Pharmaceuticals Inc showed a decrease of -1068.8% in Net Income compared to the prior fiscal year.
- Curanex Pharmaceuticals Inc reported Diluted EPS of $0.17 per share (loss) for fiscal year 2025.
- Curanex Pharmaceuticals Inc showed a decrease of -466.7% in Diluted EPS compared to the prior fiscal year.
- Curanex Pharmaceuticals Inc reported Total Assets of $11.58 million for fiscal year 2025.
- Curanex Pharmaceuticals Inc showed an increase of +2135.8% in Total Assets compared to the prior fiscal year.
- Curanex Pharmaceuticals Inc reported Stockholders Equity of $11.22 million for fiscal year 2025.
- Curanex Pharmaceuticals Inc showed an increase of +2128.8% in Stockholders Equity compared to the prior fiscal year.
- Curanex Pharmaceuticals Inc reported R&D Expense of $2.99 million for fiscal year 2025.
- Curanex Pharmaceuticals Inc reported Operating Income of -$4.24 million for fiscal year 2025.
- Curanex Pharmaceuticals Inc showed a decrease of -1061.2% in Operating Income compared to the prior fiscal year.
- Curanex Pharmaceuticals Inc reported Shares Outstanding of 28.34 million shares for fiscal year 2025.
- Curanex Pharmaceuticals Inc showed an increase of +18.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: